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Inflow Thrombosis Does Not Adversely Affect Thrombolysis Out-
comes of Symptomatic Iliofemoral Deep Venous Thrombosis
G. Jeyabalan, G. Konig, L. Marone, R. Rhee, M. Makaroun, J. Cho, and
R. Chaer, Pittsburgh, Pa
From the University of Pittsburgh Medical Center.
Background: The presence of popliteal or tibial vein clot is thought to
adversely affect thrombolysis for iliofemoral deep venous thrombosis (DVT). We
examined the effect of inflow thrombosis on functional and anatomic outcomes.
Methods: A retrospective review of 44 patients treated for symptom-
atic iliofemoral DVT between 2006 and 2009 was performed. All patients
were treated by pharmacomechanical thrombectomy with local tissue plas-
minogen activator with the Angiojet or Trellis device. Catheter-directed lysis
and vena cava filters were used sparingly. Univariate and multivariate logistic
regression analyses were used.
Results: Forty-four patients with a mean age of 52.1  15.8 years
presented with symptoms averaging 13.4  9.9 days in duration. Twenty
(45.4%) had symptoms for 14 days; 39% were treated in one session, but 27
patients required lytic infusion for residual thrombus. Iliac stentingwas required
in 49% of limbs. Successful lysis (50%) was achieved in 91% of patients, and
symptom resolution or improvement in 91%. All patients became ambulatory
with no or minimal limitation. No major systemic bleeding complications
occurred. Freedom from DVT recurrence and reintervention was 84% at 24
months by life-table analysis. On preoperative ultrasound imaging, 89% had
popliteal and tibial clot and were treated by accessing a thrombosed popliteal
vein. Only one patient required simultaneous tibial lysis. At amean follow-up of
8.7  6.3 months, 41 patients (93%) had no symptom recurrence (Fig), 82%
had preserved valve function and no reflux on duplex imaging, with a mean
CEAP class of 1.4. The presence of inflow thrombus had no adverse effect on
symptom relief, treatment duration, patency, CEAP class, or valve reflux.
Interestingly, 90% of patients with initial popliteal thrombus had a patent
popliteal vein on postlysis ultrasound imaging, and the presence of tibial
thrombus on presentation was predictive of symptom relief with thrombolysis
(odds ratio, 13.03; 95% confidence interval, 1.02-165.58; P .048).
Conclusions: Inflow thrombosis is common and does not preclude
successful thrombolysis of iliofemoral DVT. Valve function is preserved on
midterm follow-up with maintained CEAP class and symptom relief.
Objective Outcome Measures of Patients with Iliofemoral Deep Venous
Thrombosis Treated with Catheter-directed Thrombolysis
N. K. Grewal,a J. Trabal Martinez,a L. Andrews,a Z. Assi,b S. Kasanjian,b and
A. J. Comerota,a Toledo, Ohio
From the Jobst Vascular Center,a and Interventional Radiology,b The
Toledo Hospital.
Background: It has been suggested that elimination of thrombus in
patients with iliofemoral deep venous thrombosis (DVT)may reduce the risk
of the post-thrombotic syndrome (PTS). The purpose of this study was to
provide objective follow-up in patients treated with pharmacomechanical
thrombolysis or catheter-directed thrombolysis for extensive lower extrem-
ity DVT.
Methods: Patients with iliofemoral DVT who underwent catheter-
directed or pharmacomechanical thrombolysis were monitored and assessed
for signs and symptoms of PTS using validated outcome measures: the
CEAP clinical classification, the Villalta score, and the Venous Clinical
Severity Score (VCSS).
Results: Forty-eight patients underwent catheter-based treatment for
iliofemoral DVT, 21 with catheter-directed thrombolysis and 27 with phar-
macomechanical lysis. The average patient age was 46 years (range, 16-78
years). Mean percentage of clot lysis as determined by preprocedural and
postprocedural venography was 76%. Follow-up averaged 21.3 months.
Mean clinical class of CEAP and VCSS and Villalta scores were 2, 3, and 4,
respectively. Complications of thrombolysis included one acute renal failure
and two major hematomas. No intracranial bleeding or symptomatic pul-
monary embolism occurred.
Conclusions: Patients with iliofemoral DVT who underwent cath-
eter-based thrombolytic techniques to eliminate thrombus demonstrated
good technical results based on the percentage of clot lysis. This resulted
in overall good clinical scores based on the CEAP, VCSS, and Villalta
validated scoring systems. PTS was avoided as defined by the Villalta
score. These observations indicate a successful strategy of catheter-
directed thrombolysis will likely prevent the development of PTS or
substantially reduce its severity.
Anticoagulation Monitoring by an Anticoagulation Service is More
Cost-effective than Routine Physician Care
F. Aziz, M. Corder, and A. J. Comerota, Toledo, Ohio
From the Jobst Vascular Center, The Toledo Hospital.
Background: Vitamin K antagonists (VKA) are the mainstay of long-
term anticoagulation but require careful monitoring for effectiveness and
safety. Most patients are treated by physicians, although anticoagulation
services (AS) are becoming increasingly popular. A newAS run by nurses and
overseen by a physician was established, and the insurance carrier indepen-
dently assessed its effectiveness vs usual physician care. We report the
independent analysis of anticoagulation morbidity reflected by emergency
department (ED) visits and hospitalizations observed by these two para-
digms of VKA monitoring.
Methods: An independent analysis of ED visits and hospitalizations as
a consequence of anticoagulation was performed for 2397 patients receiving
VKA between July 1 and December 31, 2008. Physicians monitored 2266
patients and the newly formed AS monitored 133. The average cost of ED
visits and hospitalizations was calculated for each patient cohort. The
expense of each was amortized for 12 months to determine an annual cost of
anticoagulation morbidity per 100 patients treated.
Results: Results are summarized in the Table.
Table. Six-month data for emergency department visits
and hospitalizations related to anticoagulation
Variable
Monitoring service
TotalMD AS
Patients evaluated,
No. (%)
2266
(94.5)
131 (5.5) 2397
Emergency
department data
Visits, No. (%) 247 (10.9) 2 (1.5) 249 (12.4)
Cost per visit $288.00 $139.00
Cost per patient
treated
$31.00 $2.00
Savings per patient
treated by AS
$29.00
Annual savings/100
patients treated
$5800.00
Hospitalization data
Fig. Freedom from symptom recurrence after thrombosis for
iliofemoral DVT
787
Variable
Monitoring service
TotalMD AS
Hospitalizations,
No. (%)
289 (12.8) 3 (2.3) 292 (15.1)
Cost per
hospitalization
$15,125.00 $17,794.00
Cost per patient
treated
$1929.00 $407.00
Savings per patient
treated by AS
$1522.00
Annual savings/100
patients treated
by AS
$304,400.00
Total annual
savings/100
patients treated
by AS
$310,200.00
AS, Anticoagulation service; MD, medical doctor.
Conclusions: Management of long-term VKA therapy by an AS with
established protocols reduces anticoagulation morbidity, resulting in signif-
icant cost savings by reducing the number of ED visits and hospitalizations.
Magnetic Resonance T1-mapping Quantifies the Organization of
Resolving Venous Thrombi
P. Saha, U. Blume, A. Wiethoff, G. Varma, D. Eastham, M. Waltham,
T. Schaeffter, A. Patel, A. Ahmad, C. Evans, B. Modarai, and A. Smith,
London, United Kingdom
From King’s College London.
Background: Current imaging modalities are unable to accurately
assess the degree of organization in venous thrombi. We used a mouse
model of thrombosis to optimize and validate a novel magnetic resonance
imaging (MRI) protocol for the quantification of organization during
venous thrombus resolution.
Methods: AMR T1 relaxation mapping sequence was used to image
venous thrombi in 30 male BALB/C mice. T1 relaxation times were
quantified after 7, 10, 14, 21, and 28 days, using MATLAB and OsiriX
analysis of ParRec and DICOM data sets. Thrombus was harvested and
processed for histology after imaging from groups of mice at each time
interval (n  3/group). Sections obtained from at least 10 defined
intervals throughout the thrombus were stained for markers of organi-
zation, including red cell and collagen content (martius/scarlet/blue
stain) and hemosiderin content (Perl stain). Three blinded observers
used image analysis to calculate the percentage area of thrombus con-
taining stain and correlated these with the T1 relaxation times of the
corresponding MR scan slices.
Results: The mean T1 relaxation time of the thrombus proportionally
increased with time (Fig 1). Stronger correlations were observed between
the mean T1 relaxation time of the thrombi and collagen (Fig 2) or
hemosiderin content (R2  0.72, P  .0001). The red cell content of
thrombi had a weaker but significant correlation with T1 times (R2 0.41;
P  .01).
Conclusions:MR T1 relaxation mapping can be used as a noninvasive
method for the longitudinal quantification of thrombus organization and
requires no contrast. This technique could be used to predict clinical
outcome after deep vein thrombosis, guide management, and assess the
efficacy of treatments in both pre-clinical and clinical settings.
The Controversy of Managing Calf Vein Thrombosis: A Systematic Review
E. M. Masuda,a F. Liquido,a and Q. He,b Honolulu, Hawaii
From Straub Clinic & Hospital,a and Pacific Health Research Institute.b
Background: The lack of evidence-based data regarding the optimal
treatment of calf deep vein thrombosis (C-DVT) has resulted in controversy
about whether all C-DVT should be treated with anticoagulation or observed
with duplex surveillance. The studies published have reported highly variable
statistics on pulmonary emboli rates associated with C-DVT and clot propaga-
tion to the popliteal vein or higher. As a result, this analysis was undertaken to
determine the incidence of these events associated with C-DVT.
Methods: We reviewed 1460 articles that were published from 1975 to
2009 using computerized database searches of PubMed, Cochrane Controlled
Trials Register, and extensive cross references. The quality of the reports were
reviewed by two investigators (E.M., F.L.), and articles underwent strict selec-
tion based on specific inclusion and exclusion criteria. Studies were required to
have clear definitions of C-DVT, including involvement of muscular (soleal,
gastrocnemius) or axial veins (peroneal, posterior tibial, peroneal), or both, but
not involving the popliteal vein, clearly defined inception cohort, design by
randomized controlled trial (RCT) or prospective trial, or serial surveillance by
duplex ultrasound scanning or radionuclide testing supplemented by venogra-
phy. Only English-language articles were reviewed.
Results: Of the 1460 citations reviewed, there were 14 relevant En-
glish-language papers that met the selection criteria: 3 RCTs and 11 pro-
spective observational cohort studies. No RCTs were designed to compare
anticoagulation vs observation with duplex scan surveillance. The three
RCTs had varied regimens of anticoagulation dosing and duration. Pulmo-
nary emboli (PE) during presentation were reported up to 33%, whereas PE
during surveillance in the pooled data analysis were 3.5%, including those
treated and untreated. Propagation to the popliteal vein or higher tended to
be greater in those groups not treated with anticoagulation vs those treated
with anticoagulation.
Conclusions: Compared with PE at presentation, the incidence of PE
during surveillance of C-DVT is low. The risk of propagation to the popliteal
vein or higher must be considered in determining optimal treatment.
Scientific evidence guiding treatment is lacking, and RCT’s comparing
anticoagulation against duplex ultrasound surveillance are needed to deter-
mine the best approach.
Validation of the Caprini Risk Assessment Model in Plastic and Recon-
Structive Surgery Patients
C. J. Pannucci,a S. Bailey,b C. Fisher,c J. Clavijo-Alvarez,c J. Hamill,d
K. Hume,d T. Wakefield,a J. Rubin,c E. Wilkins,a and R. Hoxworth,b Ann
Arbor, Mich; Dallas, Tex; Pittsburgh, Pa; and Arlington Heights, Ill
From the University of Michigan, Ann Arbora; University of Texas-South-
western, Dallasb; University of Pittsburgh, Pittsburghc; and the American
Society of Plastic Surgeons, Arlington Heights.d
Background: In contrast with other surgical subspecialties, the plastic
surgery literature demonstrates a paucity of research on the efficacy of
chemoprophylaxis in venous thromboembolism (VTE) prevention. As a
result, we created a consortium of three tertiary referral centers with dem-
onstrated expertise in plastic and reconstructive surgery to perform a pro-
spective cohort study with historic controls to examine the efficacy of
low-molecular-weight heparin prophylaxis for VTE prevention in plastic
surgery patients.
Methods: A midterm analysis of the study’s control group was con-
ducted to evaluate the incidence of VTE when chemoprophylaxis is not
provided and to validate the predictive ability of the Caprini Risk Assessment
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